Veyonda (idronoxil) given in combination with low-dose radiation therapy was able to shrink metastatic lesions well outside the radiation field in about 27% of men with late-stage metastatic castration-resistant prostate cancer (mCRPC) in the DARRT-1 Phase 1 trial, updated data show. “To our knowledge, this is the first time that anyone has been able to obtain a meaningful abscopal response rate in prostate cancer,” Graham Kelly, PhD, executive chairman and CEO of Noxopharm, which is developing the therapy, said in a…
You must be logged in to read/download the full post.
The post Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial appeared first on BioNewsFeeds.